溴吡斯的明片联合甲磺酸多沙唑嗪片治疗老年女性宫颈癌术后尿潴留的临床研究  

Clinical trial of pyridostigmine combined with doxazosin mesylate in the treatment of elderly women with urinary retention after cervical cancer surgery

作　　者：苏坤华[1] 胡友斌[2] 马经明 寇莉[4] 

机构地区：[1]三峡大学第一临床医学院宜昌市中心人民医院药剂科,湖北宜昌443000 [2]三峡大学第一临床医学院宜昌市中心人民医院妇产科,湖北宜昌443000 [3]湖北省恩施土家族苗族自治州中心医院药剂科,湖北恩施445000 [4]宝鸡市人民医院妇产科,陕西宝鸡721000

出　　处：《中国临床药理学杂志》2017年第16期1537-1539,共3页The Chinese Journal of Clinical Pharmacology

基　　金：国家医学教育发展中心医学研究课题基金资助项目(2010-35-02-024)

摘　　要：目的观察溴吡斯的明联合甲磺酸多沙唑嗪治疗老年女性宫颈癌术后尿潴留的临床疗效及安全性。方法将52例老年女性宫颈癌术后尿潴留患者随机分为对照组26例与试验组26例,2组患者均给予常规物理刺激。对照组给予甲磺酸多沙唑嗪片4 mg,每日1次,口服;试验组在对照组的基础上给予溴吡斯的明片60 mg,每日3次,口服。2组患者均用药7 d。治疗后,比较2组患者的临床疗效、尿动力学水平及药物不良反应发生情况。结果治疗后,试验组的总有效率为92.31%(24/26例),对照组为65.38%(17/26例),差异有统计学意义(P<0.05)。治疗后,试验组残留尿量、膀胱最大容量、逼尿肌顺应性、最大尿流率、最大尿流率时逼尿肌压力分别为(40.14±5.57)mL,(300.19±31.89)mL,(32.00±4.18)cm H_2O,(10.02±1.43)mL·s^(-1),(25.71±3.14)cm H_2O;对照组分别为(69.88±8.37)mL,(5.02±0.53)mL,(56.39±6.19)mL·cm H_2O^(-1),(17.89±2.34)mL·s^(-1),(33.41±4.02)cm H_2O,差异均有统计学意义(P<0.05)。试验组药物不良反应有恶心、呕吐、腹泻,药物不良反应发生率为15.38%(4/26例),对照组药物不良反应有恶心、呕吐、腹泻,药物不良反应发生率为11.54%(3/26例)。2组药物不良反应发生率比较,差异无统计学意义(P>0.05)。结论溴吡斯的明联合甲磺酸多沙唑嗪治疗老年女性宫颈癌术后尿潴留的临床疗效显著,安全性较高。Objective To evaluate the clinical efficacy and safety of pyri- dostigmine combined with doxazosin mesylate in the treatment of elderly women with urinary retention after cervical cancer surgery. Methods A total of 52 cases of elderly women with urinary retention after cervical cancer surgery were randomly divided into control group （n = 26 ） and treatment group （ n = 26 ）. Patients in two groups were given routine physical stimulation. Control group was given doxazosin mesylate 4 mg qd. Treatment group was given pyridostigmine bromide tablets 60 mg tid, on the basis of control group. All patients were treated for 7 d. The clini- cal efficacy, urodynamics and adverse drug reactions were observed in two groups. Results After treatment, the total effective rates in treat- ment group and control group were 92.31% （24/26 cases）, 65.38% （ 17/26 cases）, with significant difference（P 〈0. 05）. After treatment, the residual ttrine volume, maximum bladder capacity, bladder compliance,maximum urine flow rate, detrusor pressure at maximum urinary flow rate in treatment group were （40. 14 ± 5.57 ）mL, （300. 19 ± 31.89） mL, （32. 00 ± 4. 18 ） mL · cm H2O^ - 1, （ 10. 02 ± 1.43 ） mL · s- 1, （25.71 ± 3.14） cm H2 0, had significant difference with those in control group, which were （69.88 ± 8.37 ）mL, （5.02 ± 0.53 ）mL, （56.39±6.19）cmH20-1, （17.89 ±2.34）mL · s-1, （33.41 ±4.02）cm HiO（P〈0.05）. The adverse drug reactions in treatment group were nausea and vomiting, diarrhea, total incidence of adverse drug reactions was 15.38% （4/26 cases）. The adverse drug reactions in control group were nausea and vomiting, diarrhea, the total incidence rate of adverse reaction was 11.54% （3/26 cases, P 〉 0. 05）. Conclusion Pyridostigrnine combined with doxazosin mesy- late have significant effect in the treatment of urinary retention after cervical cancer surgery in elderly women, and safety.

关 键 词：溴吡斯的明 甲磺酸多沙唑嗪 老年女性宫颈癌 尿潴留 

分 类 号：R97[医药卫生—药品]